Lupin says no revenue hit from ANVISA action
This article was originally published in Scrip
Executive Summary
Lupin's shares dipped on Indian bourses on 8 July amid news that the firm may be under fire from the Brazilian regulator, ANVISA, over certain good manufacturing practice (GMP) deviations at its cephalasporins site.